A Phase 3, Randomized,Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease |
| |
| Affiliation: | 1. Wolstan & Goldberg Eye Associates, Torrance, California;2. Ophthalmology Associates, Cornea and LaserVision Institute, St. Louis, Missouri;3. Florida Eye Microsurgical Institute, Boynton Beach, Florida;4. Sun Pharmaceutical Industries, Ltd., Princeton, New Jersey;5. i-Novion, Inc., Randolph, New Jersey;6. Virginia Eye Consultants and Eastern Virginia Medical School, Norfolk, Virginia |
| |
| Abstract: | |
| |
| Keywords: | AE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0015" }," $$" :[{" #name" :" text" ," _" :" adverse event DED" },{" #name" :" keyword" ," $" :{" id" :" kwrd0025" }," $$" :[{" #name" :" text" ," _" :" dry eye disease ITT" },{" #name" :" keyword" ," $" :{" id" :" kwrd0035" }," $$" :[{" #name" :" text" ," _" :" intention-to-treat SANDE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0045" }," $$" :[{" #name" :" text" ," _" :" Symptom Assessment iN Dry Eye SAE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0055" }," $$" :[{" #name" :" text" ," _" :" serious adverse event SE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0065" }," $$" :[{" #name" :" text" ," _" :" standard error TEAE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0075" }," $$" :[{" #name" :" text" ," _" :" treatment-emergent adverse event |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
